DBVT (DBV Technologies) 3-1 Month Momentum %: -25.09% (As of Jul. 09, 2026)


DBVT DBV Technologies SA DBVT
31 GF Score
Price $16.08
! 1 Warning Sign
View Full Analysis

What is DBV Technologies 3-1 Month Momentum %?

DBV Technologies DBVT -4.17% 31 3-1 Month Momentum % is -25.09% as of Jul. 09, 2026. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,378 Biotechnology companies, DBV Technologies ranks worse than 70.75% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-09), DBV Technologies's 3-1 Month Momentum % is -25.09%.

The industry rank for DBV Technologies's 3-1 Month Momentum % or its related term are showing as below:

DBVT's 3-1 Month Momentum % is ranked worse than
70.75% of 1378 companies
in the Biotechnology industry
Industry Median: -11.025 vs DBVT: -25.09

DBV Technologies  (NAS:DBVT) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

DBV Technologies 3-1 Month Momentum % Related Terms

DBVT vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, DBV Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where DBV Technologies's 3-1 Month Momentum % falls into.


DBVT
31GF Score
DBV Technologies SA DBVT
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies  (NAS:DBVT) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -25.09% mean?
DBV Technologies (DBVT) has a 3-1 Month Momentum % of -25.09% as of Jul. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DBV Technologies and its competitors. According to the industry distribution chart, DBV Technologies ranks #975 out of 1378 companies in the Biotechnology industry, placing it in the top 70.8%.
Is DBV Technologies' 3-1 Month Momentum % too high?
DBV Technologies' current 3-1 Month Momentum % is -25.09%. Based on the distribution chart, DBV Technologies ranks #975 out of 1378 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #975 out of 1378 companies for 3-1 Month Momentum %. This places DBV Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DBV Technologies and its competitors. DBV Technologies's current 3-1 Month Momentum % is -25.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current 3-1 Month Momentum % of -25.09%. The current 3-1 Month Momentum % is -25.09%. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For DBV Technologies (DBVT), the current 3-1 Month Momentum % is -25.09% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for DBVT

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.08
Price